KYNTRA BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
KYNTRA BIO, INC. (KYNB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $59.65 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-03-16
- KYNTRA BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $59.65, a 1180.04% increase from fiscal 2024.
- KYNTRA BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $4.66, a 79.28% decline from fiscal 2023.
- KYNTRA BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $22.49, a 31.62% decline from fiscal 2022.
- KYNTRA BIO, INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $32.89, a 3.46% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2025-12-31 | $59.65 10-K · filed 2026-03-16 |
| 2024-12-31 | $4.66 10-K · filed 2025-03-17 |
| 2023-12-31 | $22.49 10-K · filed 2024-02-26 |
| 2022-12-31 | $32.89 10-K · filed 2023-02-27 |
| 2021-12-31 | $34.07 10-K/A · filed 2022-03-04 |
| 2020-12-31 | $40.11 10-K · filed 2021-03-01 |
| 2019-12-31 | $44.65 10-K · filed 2020-03-02 |
| 2018-12-31 | $30.55 10-K · filed 2019-02-27 |
| 2017-12-31 | $22.05 10-K · filed 2018-02-27 |
| 2016-12-31 | $21.81 10-K · filed 2017-03-01 |
| 2015-12-31 | $18.08 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |